November 5, 2021 7:55am
A question of what’s considered fair value
Earnings: Cellectis SA (CLLS) and bluebird bio (BLUE)
Pre-open indications: swapping actions, 4 SELLs, 6 BUYs with 1 Pump (or No Promote)
What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.11% (+38 points), S&P futures are UP +0.19% (+9 points) and NASDAQ futures are UP +0.15% (+25 point)
Stock futures rose slightly in morning trading ahead of the highly anticipated October jobs report on Friday,
European markets were flat,
Asia-Pacific markets were mostly lower with Hong Kong-listed property developers weighing heavily on the Hang Seng index.
Economic data docket: the Labor Department's October jobs report is expected to show a pick-up in job growth after a disappointing September for rehiring.
- Consensus economists are looking to see non-farm payrolls rise by 450,000 for last month, compared to the just 194,000 brought back in September. The unemployment rate likely dipped to 4.7%, or the lowest since March 2020. And average hourly earnings likely rose at a 4.9% year-on-year pace, with wages pushed higher as companies competed for workers amid widespread labor scarcities. <Yahoo Finance>
Henry’omics:
The stock market rally continues to advance, hitting new highs…
The Nasdaq has now rallied for nine (9) straight sessions. It's now 6% above its 50-day line. The Nasdaq 100 is 6.7% above its 50-day. The 6% mark is getting extended, raising the risk of a pullback and that any such retreat could be larger. <IBD>
Earnings Results;
Cellectis SA (CLLS) had a net loss of -$37 m, a negative loss per share of -$0.82, a cash position of $216 m with solid revenue of 11 m versus $9 in Q3/20,
bluebird bio (BLUE) had a net loss of -$216.8 m, a negative loss per share of -$3.17., a cash position of $970.7 m with solid revenue of $22 m versus $19 m in Q3/20,
Note: A trial of Pfizer (PFE) up pre-open +$4.07 or +9.30%) experimental antiviral pill for COVID-19 was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday. The results appear to surpass those seen with Merck (MRK) pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.
If you didn’t remember what happen at Thursday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:
Thursday’s evening’s recap: “not quite wrong and almost totally correct. While low volume, earnings and conviction signal sector’s slight decline.” … https://www.regmedinvestors.com/articles/12169
Q4: November, 3 positive and 1 negative close to date
- October, 8 positive and 13 negative closes
Companies in my headlights – It’s your decision; I provide an idea and context:
SELL with a Pump or no promote:
Biostage (BSTG) closed flat at $2.60 with 82 shares traded after Wednesday’s -$0.40 to $2.60 with 1,208 shares traded, after Tuesday’s -$0.10 to $3.00 with 200 shares traded following Monday’s flat again with 80 shares traded and last Friday’s flat with 95 shares traded.
- What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?
- For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation.
Probabilities versus aftermarket/pre-open share pricing indication moves:
SELL from BUY:
Alnylam Pharmaceuticals (ALNY) after closing +$12.68, a pre-market of-$0.55 or -0.30%,
SELL:
Applied Genetic Technologies (AGTC) closed up +$0.19 with a pre-market of -$0.02 or -0.69%,
bluebird bio (BLUE) closed up +$0.36 with a pre-market of -$6.17 or -24.49%,
Global Blood Therapeutics (GBT) closed down -$0.89 with a pre-market of -$0.87 or -2.21%,
BUY:
uniQure NV (QURE) closed up +$0.11 with a pre-market of +$0.38 or +1.06%,
Vericel (VCEL) closed down -$1.37 with a pre-market of +$2.39 or +4.91%,
Bellicum Pharmaceuticals (BLCM) closed down -$0.05 and earnings with an aftermarket of +$0.04 or +1.95%,
Intellia Therapeutics (NTLA) closed down -$1.97 with a pre-market of +$0.16 or +0.12% earnings,
Editas Medicine (EDIT) closed down -$0.85 and earnings with an aftermarket of +$0.47 or +1.24%
Sage Therapeutics (SAGE) closed down -$0.44 and earnings with a pre-market of +$1.08 or +2.13%
The BOTTOM LINE: Keep your earnings anxiety in check.
As I had stated, “I am building a cash reservoir for I believe this market and sector is about to take a dive!”
It's highly risky to buy a stock just before earnings, and investors may want to take whole or partial profits on holdings with tiny gains.
We are seeing to date, one (1) net income – Bellicum Pharmaceuticals (BLCM)...
- Twenty-three (23) net losses to date <uniQure (QURE), Alnylam Pharmaceuticals (ALNY), Regenxbio (RGNX), Sage Therapeutics SAGE), Ultragenyx Pharmaceuticals (RARE), Voyager therapeutics (VYGR), Solid Biosciences (SLDB) and Ionis Pharmaceuticals (IONS), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA) and Caladrius Biosciences (CLBS), AxoGen (AXGN), Adverum Biotechnologies (ADVM), Verastem (VSTM), Global Blood therapeutics (GBT), Fate Therapeutics (FATE) and Sangamo Therapeutics (SGMO), bluebird bio (BLUE) and Cellectis sa (CLLS) > ...
- Releases are slowing the tug-of-war between share pricing that is softer as usual and the usual LPS (loss-per-share) to be less than estimates and expectations.
The stem, cell and gene therapy earnings with Editas Medicine (EDIT) on 11/8, Applied Genetic technologies (AGTC), Vericel (VCEL) on 11/9, BioLife Solutions (BLFS) on 11/11, Athersys (ATHX) and Brainstorm Cell Therapeutics (BCLI) coming 11/15 (to date).
I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
